What hormonal contraception is most effective for obese women?

Journal of Family Practice

Volumn 56, Issue 6, 2007, Pages 471-473

  Gordon, Lauren ^a   Thakur, Netra ^a   Atlas, Michel ^b  

^a Franklin Square Hospital Center   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT; DESOGESTREL; DRUG DERIVATIVE; ETHINYLESTRADIOL; NORGESTREL;

BODY MASS; BODY WEIGHT; DRUG EFFICACY; HORMONAL CONTRACEPTION; NOTE; OBESITY; PREGNANCY; VAGINA RING; ARTICLE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; PREGNANCY RATE; RISK ASSESSMENT;

CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DRUG COMBINATIONS; ETHINYL ESTRADIOL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; NORGESTREL; OBESITY; PREGNANCY; PREGNANCY RATE; RISK ASSESSMENT;

EID: 34347358462     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (12)

1. Holt VL, Cushing-Haugen KL, Daling JR. Body weight and the risk of oral contraceptive failure. Obstet Gynecol 2002; 99:820-827.
2. Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body Mass Index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105:46-52.
3. Vessey M, Painter R. Oral contraceptive failures and body weight: Findings in a large cohort study. J Fam Plan Reprod Health Care 2001; 27:90-91.
4. Anderson FD, Hait H. A multi-center, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68:89-106.
5. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77 (Suppl 2): S13-S18.
6. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70:269-275.
7. Dieben TO, Roumen JM, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100:585-593.
8. Westhoff C. Higher body weight does not affect NuvaRing's efficacy [abstract]. Obstet Gynecol 2005; 105(Suppl 4): 56S.
9. Weisberg E, Fraser I, Lacarra M, et al. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception 1999; 59:311-318
10. Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing device: 12 month report of a multi-center study. Contraception 1987; 36:169-179.
11. World Health Organization. Improving Access to Quality Care in Family Planning Eligibility Criteria for Contraceptive Use. Geneva: WHO; 2004.
12. ACOG Committee on Practice Bulletins - Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453-1472.